Skip Navigation


Rheumatology Advance Access originally published online on July 27, 2004
Rheumatology 2004 43(9):1069-1071; doi:10.1093/rheumatology/keh318
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/9/1069    most recent
keh318v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dawes, P. T.
Right arrow Articles by Mucklow, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dawes, P. T.
Right arrow Articles by Mucklow, J. C.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 43 No. 9 © British Society for Rheumatology 2004; all rights reserved

Editorial

TNF therapy for spondyloarthropathy: can we marshal the argument?

P. T. Dawes, J. C. Packham and J. C. Mucklow1

Staffordshire Rheumatology Centre, University Hospital of North Staffordshire NHS Trust, Haywood Hospital, High Lane, Burslem, Stoke on Trent, ST6 7AG and 1 Department of Clinical Pharmacology, University Hospital of North Staffordshire NHS Trust, City General Hospital, Stoke on Trent, UK

Correspondence to: P. T. Dawes. E-mail: PT.Dawes@uhns.nhs.uk

The first 150 words of the full text of this article appear below.

‘Health Authorities and Primary Care Groups and Trusts should not wait for guidance from NICE.’

    Lord Hunt, House of Lords, 3 April, 2001.

There is an unmet need for effective disease-modifying treatments in the spondyloarthropathies (SPAs). Comprehensive evidence is presented in this issue [1] and published elsewhere [2] for the use of anti-TNF therapy in this group of diseases. Unfortunately, the SPAs represent a group of overlapping entities that have received less attention from pharmaceutical developers in comparison to the ‘single’ heterogeneous diagnosis of rheumatoid arthritis (RA). In patients with RA, routine assessment of interventions and their outcomes has proved a powerful means of justifying biological therapies. In addition, the effectiveness of disease-modifying anti-rheumatic drugs (DMARDs), such as sulphasalazine and methotrexate, is widely accepted. Patients with SPAs suffer badly by comparison, for two reasons. First, a historical lack of cooperation and coordination has delayed the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. Collantes-Estevez, M. C. Munoz-Villanueva, P. Zarco, J. C. Torre-Alonso, J. Gratacos, C. Gonzalez, R. Sanmarti, J. D. Canete, and (Spanish Spondyloarthropathies Study Group)
Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study
Rheumatology, December 1, 2005; 44(12): 1555 - 1558.
[Abstract] [Full Text] [PDF]